Humacyte, Inc. Common Stock
HUMAHumacyte, Inc. is a biotechnology company focused on developing regenerative medicine therapies using bioengineered human tissue. Its flagship product, HUMACYTE®, is a bioengineered human acellular tissue, primarily used for vascular and tissue replacement treatments. The company aims to innovate in the field of tissue engineering to address unmet medical needs in surgery, trauma, and vascular diseases.
Company News
Humacyte published long-term clinical data showing Symvess, a bioengineered vascular conduit, maintained structural integrity over 36 months with 92.9% infection-free rates, 82.5% limb salvage at 24 months, and no unprovoked structural failures in extremity arterial trauma patients. The results represent the first prospective long-term data for a...
Several biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.
The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.
Humacyte reported Q2 2025 earnings with $0.30 million in GAAP revenue, falling short of $1.0 million analyst estimates. The company saw expanded hospital access for its lead product Symvess, with 82 civilian hospitals approved by quarter-end, and showed improved financial metrics through cost controls.
US stock futures are trading lower after a three-day advance, as investors react cautiously to President Trump's mixed tariff signals. The market is looking more balanced, having moved from 'above-trend to on-trend', according to an expert.
